Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S.

Endocrinology. 2012 Feb;153(2):985-94. doi: 10.1210/en.2011-1519.

2.
3.

Role of BRAF in thyroid oncogenesis.

Caronia LM, Phay JE, Shah MH.

Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Review.

4.

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Nucera C, Lawler J, Parangi S.

Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Review.

5.

The role of BRAF in the pathogenesis of thyroid carcinoma.

Li DD, Zhang YF, Xu HX, Zhang XP.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1068-78. Review.

PMID:
25961545
6.

Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.

Smith N, Nucera C.

J Clin Endocrinol Metab. 2015 Jan;100(1):35-42. doi: 10.1210/jc.2014-2803. Review.

7.

Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement.

Charles RP.

Curr Protoc Pharmacol. 2015 Jun 1;69:14.33.1-14. doi: 10.1002/0471141755.ph1433s69. Review.

PMID:
26344211
8.

Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

von Roemeling CA, Copland JA.

Expert Opin Ther Targets. 2016;20(2):159-66. doi: 10.1517/14728222.2016.1086341. Review.

Items per page

Supplemental Content

Support Center